Structures by: Florence A. J.
Total: 219
Creatine monohydrate
C4H9N3O2,H2O1
Journal of the Chemical Society, Faraday Transactions (1997) 93, 10 1875-1879
a=12.489(7)Å b=4.987(1)Å c=12.075(6)Å
α=90° β=108.86(3)° γ=90°
Creatine monohydrate
C4H9N3O2,H2O1
J.Chem.Soc.,Faraday Trans. (1997) 93, 1875
a=12.492(4)Å b=4.967(1)Å c=12.051(4)Å
α=90° β=109.10(2)° γ=90°
Zopiclone
C17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=15.2023(4)Å b=7.1510(1)Å c=17.6577(3)Å
α=90.0° β=111.213(1)° γ=90.0°
Zopiclone dihydrate
C17ClN6O3,2(O)
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=16.4834(1)Å b=7.1465(1)Å c=17.4026(1)Å
α=90.0° β=109.8065(4)° γ=90.0°
Zopiclone
C17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.5813(1)Å b=8.8467(1)Å c=35.6588(3)Å
α=90.0° β=90.0° γ=90.0°
Zopiclone
C17H17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.50540(10)Å b=8.7686(2)Å c=35.5277(7)Å
α=90.00° β=90.00° γ=90.00°
Zopiclone
C17H17ClN6O3
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=5.50230(10)Å b=8.7676(2)Å c=35.5314(7)Å
α=90.00° β=90.00° γ=90.00°
Zopiclone dihydrate
C17H21ClN6O5
Chemical communications (Cambridge, England) (2001) 21 2204-2205
a=16.374(4)Å b=7.030(3)Å c=17.185(2)Å
α=90° β=108.62(1)° γ=90°
4-Chlorobenzoic acid
C7H5ClO2
New Journal of Chemistry (2006) 30, 7 979
a=14.368(9)Å b=6.132(4)Å c=3.778(2)Å
α=87.46(5)° β=100.50(4)° γ=92.94(4)°
4-Chlorobenzoic acid
C7H5ClO2
New Journal of Chemistry (2006) 30, 7 979
a=14.220(6)Å b=6.087(2)Å c=3.766(1)Å
α=87.91(4)° β=100.22(3)° γ=92.97(3)°
4-Chlorobenzoic acid
C7H5ClO2
New Journal of Chemistry (2006) 30, 7 979
a=14.272(8)Å b=6.141(3)Å c=3.813(2)Å
α=88.53(4)° β=100.11(4)° γ=93.18(3)°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.6251(5)Å b=10.6442(8)Å c=24.3193(16)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.6251(5)Å b=10.6442(8)Å c=24.3193(16)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.6594(7)Å b=10.7139(11)Å c=24.359(2)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.6886(5)Å b=10.7434(7)Å c=24.4019(16)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.723(3)Å b=10.7969(12)Å c=24.4233(16)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15O2H12
New Journal of Chemistry (2009) 33, 12 2486
a=8.7652(8)Å b=10.8627(9)Å c=24.513(2)Å
α=90.00° β=90.00° γ=90.00°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.6251(5)Å b=10.6442(8)Å c=24.3193(16)Å
α=90° β=90° γ=90°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.6594(7)Å b=10.7139(11)Å c=24.359(2)Å
α=90° β=90° γ=90°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.6886(5)Å b=10.7434(7)Å c=24.4019(16)Å
α=90° β=90° γ=90°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.7228(10)Å b=10.7969(12)Å c=24.423(3)Å
α=90° β=90° γ=90°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.7652(8)Å b=10.8627(9)Å c=24.513(2)Å
α=90° β=90° γ=90°
Dibenzoylmethane
C15H12O2
New Journal of Chemistry (2009) 33, 12 2486
a=8.7669(6)Å b=10.8752(8)Å c=24.5043(18)Å
α=90° β=90° γ=90°
Olanzapine propan-1-ol
C17H20N4S,C3H8O
CrystEngComm (2018) 20, 28 3947
a=10.217(3)Å b=13.069(4)Å c=14.918(5)Å
α=90.00° β=95.342(7)° γ=90.00°
Cyheptamiede Form-III
C16H15N1O1
Chem.Commun. (2016) 52, 7384
a=9.0171(5)Å b=11.0071(6)Å c=23.9483(13)Å
α=90° β=90° γ=90°
C17H17FN3O3,5(H2O),NA
C17H17FN3O3,5(H2O),NA
CrystEngComm (2009) 11, 7 1396
a=9.624(3)Å b=9.493(3)Å c=11.471(4)Å
α=89.643(6)° β=103.304(6)° γ=88.861(6)°
Ciprofloxacin
C17H18FN3O3
CrystEngComm (2009) 11, 7 1396
a=7.9606(2)Å b=8.5798(2)Å c=10.7739(3)Å
α=87.868(3)° β=85.153(2)° γ=88.212(1)°
2(C17H17FN3O3),10(H2O),2(Na)
2(C17H17FN3O3),10(H2O),2(Na)
CrystEngComm (2009) 11, 7 1396
a=11.065(10)Å b=13.155(12)Å c=13.879(12)Å
α=90.983(14)° β=98.941(14)° γ=93.181(14)°
C17H17.50F1N3O3,Na0.50,5(H2O)
C17H17.50F1N3O3,Na0.50,5(H2O)
CrystEngComm (2009) 11, 7 1396
a=9.452(3)Å b=9.591(4)Å c=11.233(6)Å
α=85.67(2)° β=99.62(2)° γ=93.74(2)°
C17H17FN3O3,5(H2O),NA
C17H17FN3O3,5(H2O),NA
CrystEngComm (2009) 11, 7 1396
a=9.547(7)Å b=9.870(7)Å c=11.109(12)Å
α=88.79(4)° β=101.42(4)° γ=90.25(2)°
C17H17.50F1N3O3,Na0.50,5(H2O)
C17H17.50F1N3O3,Na0.50,5(H2O)
CrystEngComm (2009) 11, 7 1396
a=9.391(8)Å b=9.570(8)Å c=11.095(9)Å
α=85.247(14)° β=99.498(13)° γ=93.272(14)°
5H-dibenz(b,f)azepine-5-carboxamide 10,11-dihydro-5H- dibenz(b,f)azepine-5-carboxamide (1/1)
0.5(C15H12N2O1),0.5(C15H14N2O1)
CrystEngComm (2006) 8, 10 746
a=9.088(2)Å b=10.425(4)Å c=25.005(7)Å
α=90.00° β=90.00° γ=90.00°
C10H8Br4CuN2
C10H8Br4CuN2
CrystEngComm (2011) 13, 13 4400
a=4.058180(52)Å b=13.94699(17)Å c=12.42233(17)Å
α=90° β=90.6948(13)° γ=90°
C10H8Br4CuN2
C10H8Br4CuN2
CrystEngComm (2011) 13, 13 4400
a=4.01653(10)Å b=13.9440(2)Å c=12.3686(2)Å
α=90° β=90.526(1)° γ=90°
2(C5H5BrN),Br4Cu
2(C5H5BrN),Br4Cu
CrystEngComm (2011) 13, 13 4400
a=6.589040(79)Å b=8.60622(11)Å c=16.25227(21)Å
α=89.7895(10)° β=89.47851(91)° γ=79.0643(11)°
2(C5H5BrN),Br4Cu
2(C5H5BrN),Br4Cu
CrystEngComm (2011) 13, 13 4400
a=6.585083(72)Å b=8.604378(94)Å c=16.26256(17)Å
α=89.77059(71)° β=89.47647(62)° γ=79.11889(68)°
10,11-Dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide
C16H15NO
CrystEngComm (2008) 10, 1 26
a=5.6491(1)Å b=19.5639(4)Å c=22.0741(5)Å
α=84.2178(13)° β=88.4073(14)° γ=83.6001(13)°
(5H-dibenz(b,f)azepine-5-carboxamide)N,N-dimethyl acetamide solvate
C19H21N3O2
CrystEngComm (2008) 10, 1 23
a=7.5046(7)Å b=19.506(2)Å c=11.7808(13)Å
α=90.00° β=96.597(8)° γ=90.00°
(5H-dibenz(b,f)azepine-5-carboxamide)nitromethane solvate
C16H15N3O3
CrystEngComm (2008) 10, 1 23
a=10.9242(11)Å b=5.1617(5)Å c=26.309(3)Å
α=90.00° β=100.104(2)° γ=90.00°
(5H-dibenz(b,f)azepine-5-carboxamide) N-methylpyrrolidine solvate
C20H21N3O2
CrystEngComm (2008) 10, 1 23
a=7.5448(4)Å b=19.5119(10)Å c=11.8783(6)Å
α=90.00° β=98.013(3)° γ=90.00°
Cytenamide form II
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=5.8100(2)Å b=19.6315(5)Å c=21.7087(6)Å
α=85.918(2)° β=86.164(2)° γ=84.482(2)°
Cytenamide form I
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=33.9078(10)Å b=33.9078(10)Å c=5.6754(2)Å
α=90° β=90° γ=120°
C49H73.06Cl4N36O19.53Pt2
C49H73.06Cl4N36O19.53Pt2
Dalton Transactions (2009) 37 7695-7700
a=28.225(8)Å b=22.859(7)Å c=29.728(9)Å
α=90.00° β=98.209(4)° γ=90.00°
4-Chlorobenzoic acid
C7H5ClO2
New Journal of Chemistry (2006) 30, 7 979
a=14.210(6)Å b=6.072(2)Å c=3.747(1)Å
α=87.68(3)° β=100.32(3)° γ=93.00(3)°
4-Chlorobenzoic acid
C7H5ClO2
New Journal of Chemistry (2006) 30, 7 979
a=14.209(7)Å b=6.120(2)Å c=3.794(1)Å
α=88.31(4)° β=100.19(4)° γ=93.03(3)°
5H-Dibenz(b,f)azepine-5-carboxamide
C15H12N2O
Chem.Commun. (2011) 47, 7074
a=9.1245(5)Å b=10.4518(5)Å c=24.8224(11)Å
α=90.00° β=90.00° γ=90.00°
C20H22O14Zn2,H2O,H2O
C20H22O14Zn2,H2O,H2O
Chemical communications (Cambridge, England) (2007) 15 1532-1534
a=7.6916(15)Å b=8.5113(17)Å c=9.827(2)Å
α=68.56(3)° β=79.47(3)° γ=86.62(3)°
C20H20O10Zn2,4O
C20H20O10Zn2,4O
Chemical communications (Cambridge, England) (2007) 15 1532-1534
a=9.5471(7)Å b=7.8520(7)Å c=8.4756(6)Å
α=91.891(4)° β=107.086(3)° γ=100.815(4)°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0093(3)Å b=22.8207(8)Å c=10.4016(4)Å
α=90° β=91.416(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1345(7)Å b=23.048(3)Å c=7.4330(8)Å
α=90° β=90.449(6)° γ=90°
30:70 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.72(Br),0.28(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.2017(6)Å b=22.3376(13)Å c=10.5639(6)Å
α=90° β=90.157(3)° γ=90°
Alpha lipoicacid nicotinamide co-crystal
C8H14O2S2,C6H6N2O
CrystEngComm (2014) 16, 26 5769
a=26.292(2)Å b=5.2948(4)Å c=34.158(3)Å
α=90.00° β=90.598(4)° γ=90.00°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=10.0604(18)Å b=22.876(4)Å c=10.4041(19)Å
α=90° β=91.741(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=9.9973(13)Å b=22.788(3)Å c=10.4078(14)Å
α=90° β=91.2430(10)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1160(12)Å b=22.916(4)Å c=7.3818(13)Å
α=90° β=91.415(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1234(14)Å b=22.966(4)Å c=7.3986(14)Å
α=90° β=91.146(2)° γ=90°
(+-)-4'-methylmethcathinone hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1264(14)Å b=22.986(5)Å c=7.4072(14)Å
α=90° β=90.974(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1314(14)Å b=23.013(5)Å c=7.4180(15)Å
α=90° β=90.803(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrochloride, Mephedrone
C11H16NO,Cl
CrystEngComm (2014) 16, 26 5827
a=7.1365(14)Å b=23.041(5)Å c=7.4304(15)Å
α=90° β=90.628(2)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=5.7804(4)Å b=19.7971(14)Å c=10.5967(6)Å
α=90° β=100.841(3)° γ=90°
(+-)-4'-methylmethcathinone Hydrobromide
C11H16NO,Br
CrystEngComm (2014) 16, 26 5827
a=10.8355(19)Å b=10.2030(17)Å c=11.5425(19)Å
α=90° β=111.839(8)° γ=90°
60:40 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16NO,0.4(Br),0.6(Cl)
CrystEngComm (2014) 16, 26 5827
a=10.1409(11)Å b=22.488(3)Å c=10.4979(11)Å
α=90° β=90.359(8)° γ=90°
70:30 (+-)-4'-methylmethcathinone hydrochloride hydrobromide salt solution
C11H16Br0.30Cl0.70N1O1
CrystEngComm (2014) 16, 26 5827
a=10.1012(5)Å b=22.5506(12)Å c=10.4737(5)Å
α=90° β=90.441(3)° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
10,11-Dihydro-5H-dibenzo(b,f)azepine-5-carboxamide
C15H14N2O
CrystEngComm (2010) 12, 1 64
a=13.207(6)Å b=5.347(2)Å c=18.891(7)Å
α=90.00° β=116.37(2)° γ=90.00°
C7D16N1O2,Br
C7D16N1O2,Br
Acta Crystallographica Section B (1997) 53, 1 176-180
a=10.951(4)Å b=13.396(8)Å c=7.072(4)Å
α=90° β=108.88(3)° γ=90°
Butylparaben isonicotinamide
C11H14O3,C6H6N2O
Acta Crystallographica Section E (2016) 72, 1 53-55
a=5.6257(6)Å b=9.8661(11)Å c=14.3979(15)Å
α=90.834(7)° β=91.431(7)° γ=91.645(7)°
Amoxapine acetate acetic acid monosolvate cyclohexane hemisolvate
C17H17ClN3O,C2H3O2,C2H4O2,0.5(C6H12)
Acta Crystallographica Section E (2015) 71, 2 139-141
a=21.0726(12)Å b=6.0393(3)Å c=18.6087(10)Å
α=90.00° β=92.096(2)° γ=90.00°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8481(16)Å b=6.359(2)Å c=8.900(3)Å
α=74.49(3)° β=83.90(3)° γ=80.53(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8619(17)Å b=6.377(2)Å c=8.926(3)Å
α=74.40(3)° β=83.93(3)° γ=80.56(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8737(9)Å b=6.4046(13)Å c=8.9548(16)Å
α=74.324(17)° β=83.751(15)° γ=80.449(16)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8707(9)Å b=6.3951(12)Å c=8.9448(16)Å
α=74.368(16)° β=83.786(14)° γ=80.459(15)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8786(9)Å b=6.4126(13)Å c=8.9665(16)Å
α=74.266(16)° β=83.693(15)° γ=80.445(16)°
N-[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]- 3-[2-(2-naphthalen-1-ylethoxy)ethylsulfonyl]propylaminium benzoate
C26H31N2O5S2,C7H5O2
Acta Crystallographica Section E (2004) 60, 10 o1751-o1753
a=7.63122(17)Å b=13.6673(3)Å c=15.8058(5)Å
α=84.385(2)° β=87.4653(19)° γ=75.7135(13)°
3,4-dichloronitrobenzene--aniline (2/1)
2C6H3Cl2NO2,C6H7N
Acta Crystallographica Section E (2005) 61, 7 o2318-o2319
a=6.9774(2)Å b=10.1668(3)Å c=27.6762(7)Å
α=90.00° β=96.495(2)° γ=90.00°
Carbamazepine N,N-dimethylformamide solvate
C15H12N2O,C3H7N1O
Acta Crystallographica Section E (2005) 61, 5 o1509-o1511
a=7.7118(4)Å b=9.1503(4)Å c=11.6969(6)Å
α=100.192(3)° β=95.379(2)° γ=101.908(3)°
Hydrochlorothiazide N,N-dimethylformamide solvate
C7H8ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 5 o1730-o1732
a=7.3028(2)Å b=9.1492(2)Å c=23.6989(6)Å
α=86.1940(10)° β=89.8410(10)° γ=72.8550(10)°
Hydrochlorothiazide N,N-dimethylacetamide solvate (1/2)
C7H8ClN3O4S2,2C4H9NO
Acta Crystallographica Section E (2006) 62, 7 o2926-o2928
a=17.0841(6)Å b=7.3905(3)Å c=17.7937(7)Å
α=90.00° β=106.875(2)° γ=90.00°
Chlorothiazide dimethylformamide solvate
C7H6ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 6 o2216-o2218
a=7.9822(4)Å b=8.8830(5)Å c=11.1075(6)Å
α=86.689(3)° β=75.078(3)° γ=73.196(3)°
Hydrochlrothiazide DMSO solvate
C7H8ClN3O4S2,C2H6OS
Acta Crystallographica Section E (2006) 62, 6 o2288-o2290
a=7.5068(4)Å b=9.8272(5)Å c=10.7311(6)Å
α=85.639(3)° β=73.896(3)° γ=80.246(3)°
4-Chlorobenzoic acid N,N-dimethylformamide solvate
C7H5ClO2,C3H7NO
Acta Crystallographica Section E (2004) 60, 11 o1950-o1951
a=6.1269(2)Å b=14.6159(5)Å c=12.6541(4)Å
α=90.00° β=103.228(2)° γ=90.00°
Carbamazepine furfural hemisolvate
C15H12N2O,0.5C5H4O2
Acta Crystallographica Section E (2005) 61, 6 o1777-o1779
a=5.1815(4)Å b=26.0450(19)Å c=20.5735(15)Å
α=90.00° β=91.302(2)° γ=90.00°
Hydrochlorothiazide--methyl acetate (1/1)
C7H8ClN3O4S2,C3H6O2
Acta Crystallographica Section E (2005) 61, 9 o2974-o2977
a=9.39703(16)Å b=7.28424(16)Å c=21.9483(3)Å
α=90° β=95.8020(11)° γ=90°
(C6H3Cl2NO2)4.(C4H8N2)'
C6H3Cl2N1O2,0.25C4H8N2
Acta Crystallographica Section E (2005) 61, 11 o3666-o3667
a=7.3850(3)Å b=9.7359(3)Å c=13.7218(5)Å
α=69.347(2)° β=87.209(2)° γ=67.945(2)°
Cyclohexane-1,3-dicarboximide, acetic acid (1/1)
C8H11NO2,C2H4O2
Acta Crystallographica Section E (2006) 62, 2 o545-o547
a=6.6224(7)Å b=7.3580(8)Å c=10.7995(12)Å
α=103.598(2)° β=93.378(2)° γ=97.272(2)°
Hydrochlorothiazide aniline solvate
C7H8ClN3O4S2,C6H7N
Acta Crystallographica Section E (2005) 61, 8 o2520-o2522
a=9.7757(3)Å b=10.5004(3)Å c=15.6093(4)Å
α=90.00° β=91.692(2)° γ=90.00°
Hydrochlorothiazide--1,4-dioxane (1/1)
C7H8ClN3O4S2,C4H8O2
Acta Crystallographica Section E (2005) 61, 8 o2573-o2575
a=6.6684(2)Å b=9.8585(3)Å c=12.9149(4)Å
α=87.046(2)° β=78.017(2)° γ=70.872(2)°
2-amino-5-nitrobenzophenone
C13H10N2O3
Acta Crystallographica Section C (1998) 54, 6 856-859
a=5.7358(15)Å b=14.693(2)Å c=13.1120(12)Å
α=90.00° β=98.87(4)° γ=90.00°
2-methylamino-9-fluoro-5-nitrobenzophenone
C14H11FN2O3
Acta Crystallographica Section C (1998) 54, 6 856-859
a=4.2150(17)Å b=13.6020(18)Å c=21.547(7)Å
α=90.00° β=94.7480(11)° γ=90.00°
2-Methylamino-5-chlorobenzophenone
C14H12ClNO
Acta Crystallographica Section C (1997) 53, 4 476-477
a=12.928(5)Å b=5.546(5)Å c=16.445(5)Å
α=90° β=92.392(5)° γ=90°
Ibuprofen
C13H18O2
Acta Crystallographica Section C (1997) 53, 951-954
a=14.397(8)Å b=7.818(4)Å c=10.506(6)Å
α=90° β=99.70(3)° γ=90°
C5H10N2O3S
C5H10N2O3S
Acta Crystallographica Section C (1999) 55, 2 232-234
a=9.088(2)Å b=8.108(2)Å c=10.505(2)Å
α=90° β=102.140(10)° γ=90°
C12H24N6O6S3
C12H24N6O6S3
Acta Crystallographica Section C (1999) 55, 2 232-234
a=14.5300(10)Å b=8.0567(8)Å c=15.928(2)Å
α=90° β=101.642(8)° γ=90°
Hydrochlorothiazide N-methyl-2-pyrrolidone disolvate
C7H8ClN3O4S2,2C5H9NO
Acta Crystallographica Section E (2006) 62, 11 o5169-o5171
a=17.0756(6)Å b=7.4819(3)Å c=17.9978(6)Å
α=90.00° β=105.211(2)° γ=90.00°
Trichlormethiazide
C8H8Cl3N3O4S2
Acta Crystallographica Section E (2007) 63, 9 o3685-o3685
a=8.7881(2)Å b=9.7924(2)Å c=15.8527(3)Å
α=90.00° β=90.00° γ=90.00°